Solbase

Quick links to important sections

Solbase

Method of action: Laxative

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Solbase

Property Description
Active Ingredient Macrogol (Polyethylene Glycol, PEG)
Form Powder for oral solution, Oral solution
Pharmacological Class Osmotic laxative (Gastrointestinal agent)
Common Use Relief of constipation
Origin Synthetic polymer

Solbase is a medicinal preparation whose primary active component is Macrogol, the internationally recognized non-proprietary name (INN) for Polyethylene Glycol (PEG). Solbase is classified as an osmotic laxative, a sub-class of gastrointestinal agents used for the relief of constipation. The medication is administered via the oral route, typically prepared as a solution from a powder for oral solution.

Composition, Form, and Origin of Macrogol

The Macrogol in Solbase is a synthetic polymer characterized chemically as an inert and non-absorbable substance. This is a key differentiator, as its lack of systemic absorption minimizes the risk of metabolic interactions associated with other drug classes. The substance does not break down or enter the bloodstream to an appreciable extent for systemic absorption, localizing its therapeutic effect entirely within the gut lumen.

How Solbase Provides General Relief

The function of Solbase is based on the physical principle of osmosis. The polymer draws and holds water molecules within the colon, preventing the reabsorption of fluid and resulting in water retention in the stool. This physical effect—which achieves both stool softening and an increase in stool volume—is the core reason Solbase is used to provide gentle, predictable relief for uncomfortable symptoms of constipation.

What side effects are possible with Solbase?

Possible Side Effects and Safety Information

The safety profile of Solbase, which contains Macrogol (Polyethylene Glycol), is based on regulatory classifications of adverse reactions, primarily reflecting its non-systemic, localized action within the gastrointestinal tract. Most commonly documented effects are related to the GI system and are dose-dependent.

Classification Representative Adverse Reactions
Common (up to 1 in 10) Abdominal pain, bloating, nausea, and diarrhea.
Uncommon (up to 1 in 100) Vomiting and an urgent need to go to the toilet.
Not Known (frequency not estimated) Allergic reactions, including anaphylaxis, angioedema, difficulty breathing, rash, and urticaria.

Serious adverse reactions documented in regulatory sources include the potential for severe allergic reactions, which may involve collapse or severe respiratory distress. The product's use is also associated with a documented risk of fluid and electrolyte disturbances in rare cases, which can, in turn, be linked to cardiac arrhythmias or seizures in high-risk patients. These imbalances are typically a concern during prolonged or excessive use.

Population-Specific Safety: Regulatory documents advise specific monitoring for individuals documented to be at increased risk of fluid and electrolyte changes, such as older adults or those taking diuretics. Safety notes also exist regarding neuropsychiatric events reported in pediatric patients on long-term Macrogol therapy.

Restrictions: Solbase is officially contraindicated in patients with conditions such as known or suspected gastrointestinal obstruction, bowel perforation, toxic megacolon, or known hypersensitivity to any component. Additionally, government safety updates note that Macrogol may reduce the effectiveness of starch-based food thickeners, posing a safety consideration for patients with swallowing difficulties.

Overdose and Emergency Response

Overdose Manifestations and Severe Outcomes

An overdose of Solbase (Macrogol) is officially documented to present with severe gastrointestinal manifestations. These signs include excessive diarrhoea, persistent abdominal pain, vomiting, nausea, and severe abdominal distension. The critical physiological risk is not systemic toxicity, but rather extensive fluid loss, leading to severe dehydration and profound electrolyte disturbances, such as hypokalemia or hyponatremia. Severe outcomes linked to these imbalances, including cardiac arrhythmias and seizures, have been officially documented. Special attention is required for the elderly and those with impaired renal or hepatic function, as they are more susceptible to severe electrolytic disorders.

Emergency Actions and Management

Regulatory guidance mandates that individuals seek immediate medical attention for any suspected overdose and contact a Poison Control Center right away. Urgent emergency services must be called if the individual collapses, has a seizure, has trouble breathing, or cannot be awakened. No specific antidote is known for Macrogol overdose. Official management involves instituting symptomatic and supportive treatment, with the essential focus being the immediate correction of all fluid and electrolyte deficits. Monitoring may be required, including laboratory testing (electrolytes, BUN, creatinine) and ECGs, to assess for severe complications.

Therapeutic Uses of Solbase

The primary therapeutic benefit of Solbase is targeted symptomatic relief within the gastrointestinal domain, focusing specifically on difficulties related to bowel function and stool passage. Macrogol is commonly used for the treatment of both chronic constipation and faecal impaction.

Relief of Constipation and Symptom Management

Solbase is commonly used as a starting treatment option for the long-term management of persistent chronic functional constipation in adults and children. It helps address symptom clusters that may become intense or disruptive, including infrequent bowel movements, persistent straining, and the resulting difficult or painful defecation. It is applied in situations involving certain distressing symptoms and supports symptomatic relief relevant for easing the passage of stools.

“The primary benefit is often considered to be the support of a regular and more comfortable pattern of bowel function.”

The medication is also relevant for individuals experiencing secondary constipation caused by other factors, such as necessary long-term medications, and is applied in clinical settings that require additional symptomatic support, including support for the management of faecal impaction (a severe accumulation of hardened stool). Generally, this approach may help ease the overall symptom load of associated discomfort, such as bloating and the sensation of incomplete emptying.


Quick Fact: Relief for Hard Stools
Solbase is relevant for easing symptoms related to hard, dry stools, which may assist with supporting functional stability and supports general well-being during symptomatic periods.

Regulatory References

  1. National Institutes of Health (NIH) StatPearls

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Solbase — Official Regulatory Information

The eligibility profile for Solbase (Macrogol) is defined by specific population criteria and absolute exclusions detailed in official governmental labeling. These rules govern who is allowed to use the medicine and who must not use it.


Eligibility Scope

Category Official Regulatory Status (Based on Macrogol Labeling)
Populations for whom use is allowed Adults, adolescents (age minimum varies by formulation), older people, pregnant women, and breastfeeding women.
Populations for whom use is contraindicated Known Hypersensitivity to Macrogol; Bowel Obstruction (Ileus); Intestinal Perforation; severe Inflammatory Bowel Disease (Crohn's Disease, Ulcerative Colitis); or Toxic Megacolon.

Age-Related and Condition-Specific Eligibility

Category Regulatory Restriction/Caution
Age-related eligibility rules Use in children below 12 years is generally not recommended for adult-strength formulations; specific pediatric formulations are available.
Condition-specific eligibility rules Patients with Impaired Renal or Hepatic Function should use with caution due to the risk of water-electrolyte imbalance and may require monitoring.
Pregnancy and lactation eligibility Allowed during both pregnancy and lactation, as systemic exposure to the active ingredient is negligible.

Connection to the overall eligibility profile:

Regulatory documents primarily define non-eligibility through absolute gastrointestinal contraindications that prohibit use when the bowel wall is compromised. Allowance for use during pregnancy, lactation, and in most populations is based on Macrogol's non-absorbed nature. Conditional use is restricted to populations at risk of electrolyte disturbance, requiring medical attention.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Solbase (Macrogol) exhibits two primary, officially documented interaction patterns based on its physical mechanism of action, which are specified in regulatory prescribing information.

Pharmacokinetic Interaction (Reduced Absorption)

Co-administration with any oral medication carries a documented risk of reduced systemic exposure (decreased C max and AUC) of the co-administered drug. This interaction is due to Macrogol's osmotic effect, which accelerates gastrointestinal transit time. To mitigate this risk, official regulatory guidance mandates timing-separation requirements. For certain oral medications, this requires administration at a separate interval, such as at least two hours before and not less than six hours after taking Solbase, depending on the specific product label.

Pharmacodynamic Interaction (Additive Electrolyte Risk)

Concomitant use with other medicines that affect fluid and electrolyte balance can result in an additive risk of fluid and serum chemistry abnormalities. Specific drug categories noted in official documents include Diuretics (e.g., Loop diuretics), ACE inhibitors, ARBs, and NSAIDs. Co-administration with these agents may increase the formal risk of serious adverse effects such as cardiac arrhythmias or renal impairment.

No formal interactions with food, alcohol, or herbal products are documented in the official labeling for the laxative product. Due to the lack of systemic absorption, regulatory documents do not report any CYP-mediated or transporter-based interactions. This risk of electrolyte disturbance is noted to be heightened in elderly patients and those with impaired renal function.

Mechanism of Action

How Solbase Works

Solbase exerts its pharmacodynamic action through the Targeted Modulation of Specific Receptor Systems. The compound features high-affinity binding to a defined class of receptors or enzyme systems located within the cell. This interaction functions to either block or activate the primary target, thus directly interfering with the transmission of signaling at the cellular membrane level.

This primary event leads to the Regulation of Downstream Signal Transduction. By altering initial receptor activity, Solbase influences molecular cascades, effectively suppressing or limiting the propagation of secondary messengers within the cell. These messengers are chemical signals that influence the subsequent cellular response and downstream pathway activity.

The mechanism culminates in the Adjustment of Physiological Dynamics. The drug's targeted interference within these specific pathways engages mechanisms that influence regulatory feedback systems. This overall action alters the rate of signaling and modulates activity within the targeted pathways, resulting in a direct adjustment of cellular activity within the biological systems.

Dosage and Administration Information

Administration Guidelines for Solbase

Solbase is administered exclusively via the oral route as a solution reconstituted from a powder. The method of use, including dose, frequency, and duration, is defined by clinical documentation.

Dosing and Preparation

For Chronic Constipation (Adults/Adolescents 12 years), the usual starting dose is one sachet daily. The dose can be adjusted based on the individual's response, up to a maximum of three sachets daily, taken in divided doses. For administration, the contents of a single adult-strength sachet must be fully dissolved in 125 mL of water. The solution may be taken at any time of the day, with or without food.

For the treatment of Faecal Impaction (a severe accumulation of hardened stool), the regimen is eight sachets daily. This dose is typically limited to a course of up to three days, with the full daily amount consumed in divided doses within a six-hour period. For patients with impaired cardiovascular function, this dose should be further divided so that no more than two sachets are taken in any one hour. Patients with renal impairment require no specific dose change.

Administration Scope Summary of Use
Route of administration Oral use only (reconstituted solution)
Frequency pattern Once daily (standard) or divided doses
Course duration Up to two weeks for short-term use

If a dose is missed, patients should skip the missed dose and take the next scheduled dose at the usual time; doubling the next dose to compensate is not recommended. These instructions define the preparation and administration parameters for both maintenance and acute care.

Recent Clinical Evidence

Solbase: Recent Clinical Evidence


Evidence for Use in Chronic Functional Constipation

Research has studied Solbase in the context of chronic functional constipation. The core of this evidence comes from numerous Randomized Controlled Trials (RCTs) and Systematic Reviews. These studies were used in research exploring how symptoms change over time and included a broad range of adult and pediatric populations. The primary measurements tracked included weekly bowel movement frequency, outcomes related to systemic or functional imbalance (like stool consistency via the Bristol Stool Form Scale), and patient-reported outcomes describing perceived discomfort.

Studies monitored and described patterns related to the weekly frequency of bowel movements and the distribution of stool consistency scores during the observed periods. Research highlights functional changes measured during the short-term study period, where patterns related to softer stool consistency were observed. Systematic reviews utilized the consistency of reported functional outcomes to categorize the evidence as High level for this research area.


Research Evidence for Faecal Impaction

Macrogol was studied for the acute management of faecal impaction, which is a condition associated with acute or disruptive episodes. This research primarily involved short-course randomized trials over a defined time interval of three to six days. The core measurement for these trials was the rate of successful clearance of the impacted stool mass.

The primary research for faecal impaction has a strong focus on the pediatric population, meaning results apply only to the populations studied, and data extrapolation to the general adult population is limited. Follow-up durations were restricted only to the acute clearance phase, and there is limited information for long-term outcomes following successful disimpaction.


Gaps and Uncertainties in the Research Record

The research provides context but not individual predictions; the evidence highlights what is known—and what is still uncertain. Follow-up durations were limited for long-term outcomes; therefore, long-term effects are not fully established regarding sustained functional change. Data for certain groups, particularly adults with complex comorbid conditions, remain insufficient, and comparative evidence is lacking in many areas.

Key Studies & References

  1. Macrogol (polyethylene glycol) 4000 without electrolytes in the symptomatic treatment of chronic constipation: a profile of its use - PMC
  2. National clinical constipation pathway for primary care for children - NHS England (Based on NICE guidance)
  3. The macrogol revolution in the treatment of chronic constipation. A short history of laxatives

Frequently Asked Questions (FAQ)

Common questions about Solbase (FAQ)

Q: How quickly does Solbase typically start working after I begin taking it?

A: Official information describes Solbase as a gradual-acting osmotic laxative. Regulatory documents state that the medicine typically begins to produce an effect within one to two days after the first administration.


Q: How long does Solbase stay in the body?

A: According to the official product information, the active ingredient, Macrogol, is not absorbed into the bloodstream or broken down by the body. This non-systemic action means its therapeutic effect is localized entirely within the gut lumen, and the substance is expected to pass through the digestive tract unchanged.


Q: Is Solbase available over-the-counter or does it require a prescription?

A: The active ingredient in Solbase is regulated for use in different formulations. Depending on the strength and specific product, it is available in both over-the-counter (OTC) options and products that require a prescription.


Q: Can Solbase affect fertility in men or women?

A: Official documents do not typically detail effects on fertility. However, the medicine's non-absorbed nature—meaning it does not enter the bloodstream—is the basis for its allowance during pregnancy and lactation, which is a consideration in the official safety profile.


Q: Is Solbase habit-forming or addictive?

A: Based on clinical and medical literature, the active ingredient in Solbase is described as not being associated with dependency. It is an osmotic laxative often noted as suitable for long-term use in certain circumstances.


Q: Does Solbase interact with hormonal birth control?

A: Official documentation notes that Solbase can accelerate intestinal transit and may influence the absorption of any orally administered medicine. However, no formal interaction specific to hormonal birth control is documented in the official prescribing information.


Q: Does Solbase affect alertness or driving ability?

A: Regulatory documents explicitly state the status of the research in this area. Official prescribing information notes that no specific studies have been performed to assess the effects of Macrogol on the ability to drive or operate machinery.


Q: Where can I find the official prescribing information for Solbase?

A: The official prescribing information for Solbase (Macrogol) is available on government websites, such as those belonging to the FDA, EMA, or other national health regulatory authorities.


Q: Is Solbase considered a 'new' drug?

A: Macrogol, the active component of Solbase, is not considered a new medication. The substance was approved for medical use in the United States in 1999 and has a history of clinical use dating back to the 1980s.


Q: Does Solbase contain any common allergens like gluten or lactose?

A: Official documents list the excipients, or inactive ingredients, contained in specific Solbase formulations. These inactive components may include substances such as sorbitol or electrolytes. Full details regarding all ingredients are provided on the specific product label.


Q: Are there any specific lifestyle changes recommended while on Solbase?

A: Regulatory guidance notes that the use of Solbase should be complementary to appropriate lifestyle choices and dietary habits. This generally includes maintaining adequate fluid intake and adhering to a healthy diet.


Q: What should I do if I have a severe reaction to Solbase?

A: For severe allergic reactions, such as difficulty breathing, swelling, or collapse, official instructions state that the product should be discontinued and medical assistance should be sought immediately.


Q: Can Solbase be taken by children?

A: Official documents describe the use of Macrogol in both adults and children. Standard adult formulations often specify a minimum age (e.g., 12 years). Specific pediatric products are available, and use in younger children typically requires medical guidance.


Q: Are there any known long-term side effects associated with Solbase?

A: While the active ingredient, Macrogol, is described in medical literature as suitable for long-term use, regulatory documents state that the potential for fluid and electrolyte disturbances is a concern during prolonged or excessive administration.


Q: Can Solbase be taken with common pain relievers like ibuprofen or acetaminophen?

A: Official information notes an increased risk of fluid and serum chemistry abnormalities when taken with certain drug classes, including NSAIDs (such as ibuprofen). Due to its physical mechanism, Solbase may also reduce the absorption of any orally administered medicine.


Q: Has Solbase been studied in people with kidney problems?

A: Official regulatory information advises caution regarding the use of Macrogol in patients with impaired kidney function. This caution is due to the potential risk of fluid and electrolyte imbalances, and patients with this condition may require specific monitoring.


Q: What should be avoided while using Solbase?

A: Solbase is contraindicated in patients with certain severe gastrointestinal conditions, such as bowel obstruction or perforation. Caution is also advised regarding co-administration with other medicines like diuretics or NSAIDs due to potential interaction risks.


Q: Is there a maximum time someone can stay on Solbase?

A: For continuous daily use, regulatory information advises patients that if constipation symptoms persist for more than two weeks, further medical advice should be sought. Despite this short-term recommendation, Solbase is also described in official documents as suitable for long-term treatment.


Q: Are there different strengths or dosages of Solbase available?

A: The active ingredient, Macrogol, is available in different molecular weight and strength formulations in sachet form. For example, formulations of 10g or 13.8g may be available, and specific pediatric formulations also exist.


Q: Does Solbase interact with supplements like St. John's Wort or fish oil?

A: Official documents state there are no formal interactions documented with herbal products. However, due to its physical action, Solbase may reduce the absorption of any co-administered oral medication, including supplements.


Q: Can I crush or split the Solbase tablet?

A: Solbase is provided as a powder in a sachet, not a tablet. As instructed in the official administration guidelines, the powder must be fully dissolved in a specified amount of water before consumption.


Q: How does the mechanism of action of Solbase differ from older drugs in its class?

A: Official documents describe the mechanism of action as an osmotic effect, where the substance is inert and non-absorbed by the body. This localizes the effect entirely to the gut, drawing water into the stool to soften it and increase its volume.


Q: Does taking Solbase affect blood pressure readings?

A: Official documents do not state that Solbase has a direct documented effect on blood pressure. However, regulatory information notes that the potential for fluid and electrolyte disturbances is a known risk in certain patients, and these imbalances have been linked to cardiac rhythm abnormalities.


Q: Do I need to get blood tests while taking Solbase?

A: Official prescribing information advises that patients with certain risk factors may require monitoring of fluid and electrolyte levels. This caution applies to populations such as the elderly or those with impaired kidney or liver function.


Q: Are the reported side effects of Solbase generally mild?

A: The most common reported side effects, according to official regulatory documents, are generally mild and include temporary gastrointestinal disturbances. However, the documentation also notes the potential for rare, serious reactions, such as severe allergic responses.


Q: Can I take Solbase if I have a history of heart problems?

A: Official documents advise caution, particularly for patients with impaired cardiovascular function. This is due to the potential risk of fluid and electrolyte imbalances, which have been linked to cardiac rhythm abnormalities in susceptible individuals.


Q: Does Solbase interact with common over-the-counter cold and flu medications?

A: The drug's physical action can accelerate intestinal transit and potentially reduce the absorption of any co-administered oral medication. Specific drug classes, like NSAIDs often found in cold/flu meds, also carry an additive risk of electrolyte imbalance.

How should Solbase be stored and disposed of?

Official Storage and Handling Requirements

Solbase must be stored according to the official regulatory instructions to maintain its integrity. The required storage temperature is typically controlled room temperature, ranging from 20 mathrmC to 25 mathrmC. It is critical to protect Solbase from light and moisture by keeping it in its original, tightly closed container.

Prohibited Conditions and Stability

Official labeling strictly prohibits storing the product in certain environments. Do not freeze Solbase, and do not expose it to temperatures above 30 mathrmC. Always inspect the expiration date and discard the product if it has passed.

Disposal and Child Safety

For public safety, Solbase must be kept out of the sight and reach of children.

Regulatory agencies instruct patients on proper drug disposal to avoid environmental contamination. Do not dispose of Solbase by flushing it down a toilet or pouring it down a drain. Unused or expired medication should be returned to a designated medicine take-back program or official collection site.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Solbase found in:

A-Z Index: